Correlative studies in neuro-oncology trials: Should they influence treatment?

被引：6

作者：

Hegi M.E. ^{[1
]}

Stupp R. ^{[1
]}

机构：

[1] Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne

来源：

Current Oncology Reports | 2006年 / 8卷 / 1期

关键词：

Epidermal Growth Factor Receptor; Clin Oncol; Erlotinib; Temozolomide; Epidermal Growth Factor Receptor Mutation;

D O I：

10.1007/s11912-006-0010-z

中图分类号：

学科分类号：

摘要：

Recent molecular correlative studies accompanying clinical trials in glioma have provided strong evidence for prognostic markers and predictive factors for treatment response. However, to what extent can these markers influence the limited choice of therapeutic options? Do we further validate the markers in the next trials or move on, incorporate the markers for patient selection or stratification, aim at improving the modestly effective treatments by adding new drugs, and develop alternative therapy strategies for patients selected for their bad predictor? Copyright © 2006 by Current Science Inc.

引用

页码：54 / 57

页数：3

共 38 条

[1]

Godard S., Getz G., Delorenzi M., Et al., Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes, Cancer Res, 63, pp. 6613-6625, (2003)

[2]

Misra A., Pellarin M., Nigro J., Et al., Array comparative gemomic hybridization identifies genetic subgroups in grade 4 human astrocytoma, Clin Cancer Res, 11, pp. 2907-2918, (2005)

[3]

Watanabe K., Tachibana O., Sata K., Et al., Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas, Brain Pathol, 6, pp. 217-223, (1996)

[4]

Cairncross J.G., Ueki K., Zlatescu M.C., Et al., Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, 90, pp. 1473-1479, (1998)

[5]

Smith J.S., Perry A., Borell T.J., Et al., Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas, J Clin Oncol, 18, pp. 636-645, (2000)

[6]

Cairncross G., Seiferheld W., Shaw E., Et al., An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02, J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22, 14 S, (2004)

[7]

van den Bent M.J., Delattre J.-Y., Brandes A.A., Et al., First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma, J Clin Oncol, 23, 16 SUPPL., (2005)

[8]

Burger P.C., What is an oligodendroglioma?, Brain Pathol, 12, pp. 257-259, (2002)

[9]

Choe G., Horvath S., Cloughesy T.F., Et al., Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo, Cancer Res, 63, pp. 2742-2746, (2003)

[10]

Montgomery R.B., Moscatello D.K., Wong A.J., Et al., Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor, J Biol Chem, 270, pp. 30562-30566, (1995)

← 1 2 3 4 →